.7% of all samples tested, and no significant differences in sensitivity or specificity were noted between HSCT and non-HSCT patients. IAs, while not as sensitive as direct fecal CBA, produce reasonable predictive values, especially when both antigen and toxin are detected. They also offer significant advantages over CBA in terms of turnaround time and ease of use.
tigen, or metabolic end product analysis for isocaproic acid by gas-liquid chromatography (15) . However, these methods are nonspecific in that both toxigenic and nontoxigenic strains of C. difficile are identified. A latex agglutination toxin test and C. difficile PCR protocols have also been described but are not in widespread use (13, 14) . The current standard is the cytotoxin B assay (CBA). It is most commonly performed directly on feces, where it typically displays Յ85% sensitivity (5, 20) . This sensitivity may be increased to Ͼ99% by combining CBA with toxigenic culture (i.e., C. difficile culture followed by CBA performed on the culture broth), but this increase comes at a cost of increased turnaround time (5, 26) . However, CBA is not standardized, requires tissue culture facilities, and has a turnaround time of at least 24 h to 4 days (26, 31) .
In recent years, IAs for the detection of C. difficile toxins, sometimes combined with C. difficile common-antigen detection, have become available. These newer tests have been reported to approach the sensitivity of direct CBA, are specific, and offer significant advantages in terms of turn around time, cost, and ease of performance (14, 17, 22, 28, 29, 33) . In this study, we tested over 1,000 fecal samples to evaluate the performance of the following commercial IAs in comparison with direct CBA: Prima System Clostridium difficile Tox A (Prima A; Bartels Inc., now Trinity Biotech, Bray, Ireland) and VIDAS Clostridium difficile Tox A II (VIDAS A; bioMérieux Vitek, Inc., Hazelwood, Mo.), which detect C. difficile toxin A; Premier Cytoclone A/B (Cytoclone A/B; Meridian Diagnostics Inc., Cincinnati, Ohio) and Clostridium difficile Tox A/B (Tox A/B; Techlab Inc., Blacksburg, Va.), which detect toxins A and B; and the ImmunoCard Clostridium difficile (ICard; Meridian Diagnostics Inc.) and Triage Micro C. difficile (Triage; Biosite Diagnostics, San Diego, Calif.) panels, which detect toxin A and the glutamate dehydrogenase common antigen.
MATERIALS AND METHODS
Test methodology. A total of 1,003 consecutive, nonduplicate, fecal specimens of any consistency from patients at Children's Hospital and Regional Medical Center, Fred Hutchinson Cancer Research Center, Harborview Medical Center, and University of Washington Medical Center submitted for CBA during a 7-month period were selected for this study. Each sample was stored at 4°C and then tested by CBA at the University of Washington Medical Center Virology Laboratory within 24 h of receipt. Aliquots were also made and stored at Ϫ20°C for IA testing.
CBA. A modification of the CBA protocol of Rifkin et al. (27) was used. Briefly, fecal specimens were diluted 1:3 in Hanks balanced salts solution with antibiotics and centrifuged, and the supernatant was collected. The supernatant was then filtered through a 0.8-m-pore-size filter. A 100-l portion of each supernatant was added to previously prepared confluent human diploid fibroblast cell monolayers in 96-well microtiter plates, with and without the addition of Clostridium sordellii antitoxin (Burroughs-Wellcome Research Laboratories, Beckenhem, England) that has been titrated against a standard made up of four known positive fecal samples. Plates were covered, incubated at 35°C in 5% CO 2 , and then examined at 24 and 48 h for cytopathic effects characteristic of C. difficile toxin B. Samples producing cytopathic effects in the well without C. sordellii antitoxin but not in the C. sordellii antitoxin-containing well were considered positive for C. difficile toxin B. A positive C. difficile toxin B control (TechLab) was included with each run.
IA. All IAs are qualitative and were performed as recommended by the manufacturer. Cytoclone A/B and Tox A/B use a 96-microwell IA format to simultaneously detect C. difficile toxins A and B, while Prima A uses an 8-microwell IA strip format to detect toxin A. The Cytoclone A/B and Tox A/B assays were performed by manually washing the plates between steps, while a semiautomatic plate washer was used for Prima A. All three used a semiautomated plate reader to determine the final optical densities. ICard and Triage utilize single-use cards with membrane IA technologies. Triage combines C. difficile common antigen and toxin A detection on a single card, while ICard uses separate cards to detect the common antigen and toxin A. VIDAS A is a semiautomated enzyme-linked fluorescence immunoassay for the detection of toxin A and is performed on the VIDAS (bioMérieux), a proprietary, multiple-analyte analyzer.
Statistical analysis. Each sample was initially tested by all methods, with the exception of two samples that were not tested by Cytoclone A/B, one that was not tested by Triage, and one that was not tested by Prima A. Any indeterminate result led to a single retest by the same method; a second indeterminate result led to disqualification of that sample from further evaluation by that method, while definitive answers by other methods were accepted.
Calculations of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) have been previously described (21) . For the ICard panel and Triage panel statistics, true-positive and -negative results were considered to be obtained from samples that yielded all-positive or all-negative results, respectively, for the CBA, common-antigen, and toxin tests; false-positive results were obtained from samples that yielded either a positive commonantigen result, a positive toxin result, or both, but were CBA negative; falsenegative results were obtained from CBA-positive samples that gave a negative common-antigen result, a negative toxin result, or both. The interpopulation comparison analysis was done using generalized estimating equation modeling (18) .
RESULTS
Reference method results. A total of 101 (10%) of 1,003 fecal specimens were positive for C. difficile toxin B by CBA.
IA results. The performance of all IAs in comparison to CBA is displayed in Table 1 . For the samples that were tested by all methods (n ϭ 920), CBA and all toxin/C. difficile common-antigen tests were in complete agreement for 813 samples (88.4%) (766 negative and 47 positive); CBA and all toxin tests alone were in complete agreement for 903 samples (98.2%) (855 negative and 48 positive).
The sensitivity, specificity, and predictive values of each IA compared to CBA are given in Table 2 for all patients. For all tests (i.e., toxin and antigen tests), the sensitivities ranged from 55.4% (NPV ϭ 94.9%) for the ICard panel to 89.1% (NPV ϭ 98.7%) for the Triage antigen while specificities ranged from 89.7% (PPV ϭ 39.2%) for the Triage panel to 99.7% (NPV ϭ 95.0%) for ICard toxin A. For toxin tests only, sensitivities ranged from 56.4% (NPV ϭ 95.3%) for ICard toxin A to 82.2% (NPV ϭ 98.0%) for Prima A while specificities ranged from 98.3% (PPV ϭ 84.7%) for Prima A to 99.7% (PPV ϭ 95.0%) for ICard toxin A.
Of 1,003 samples, 448 (44.7%) were derived from hematopoietic stem cell transplant (HSCT) patients at one institution (Fred Hutchinson Cancer Research Center). No significant differences in sensitivity (P ϭ 0.55) or specificity (P ϭ 0.23) associated with HSCT versus non-HSCT patients were identi- 
DISCUSSION
Current laboratory diagnosis of CDD is based on either the detection of C. difficile in feces by culture on selective media or on the detection of a C. difficile surrogate marker antigen or its toxins (the latter by CBA until recently). Organism identification by culture or antigen detection is, however, nonspecific in that these methods detect both toxigenic and nontoxigenic strains. While sensitive and specific, the widely accepted CBA has several limitations in that it is not standardized, has a relatively long turnaround time (TAT) of Ͼ48 h, and requires tissue culture facilities. Although lack of standardization is perhaps not a practical limitation in that interlaboratory comparison of data is not common outside of proficiency testing, the other two factors must be considered. Numerous commercial IA methods are now available that, while not being the equal of CBA in terms of sensitivity, offer important advantages in terms of decreased TAT and ease of use. Previous studies comparing these IAs to CBA have been hampered by the fact that they have evaluated one or at most several of the former in a given study. We have attempted to address this by comparing a large selection of commercial C. difficile IAs to the direct detection of fecal toxin B by CBA.
Regarding C. difficile toxin detection alone, we found a wide range of performance among the various IA methods. In general, the toxin A portions of the ICard and Triage panels (the two assays using a single-use card format) were notably inferior in terms of sensitivity but, conversely, had the highest specificities compared to the other assays, with differences in sensitivity being much more apparent. When adjusted for prevalence, as determined by PPV and NPV, these differences remained. These data support the findings of others that the single-use card format is inferior to traditional enzyme-linked immunosorbent assay from the perspective of its ability to detect its analyte (24) . In contrast, other workers have found that the single-use card IA format can be equal to or better than microwell IA (8, 32) . Overall, the Tox A/B test had the best performance among the toxin-only tests, having the highest PPV and the second highest NPV. In addition, the Tox A/B test performs assays for both C. difficile toxins A and B: while strains producing only one of the two toxins do not appear to be common, they have been implicated in human disease (2, 19) .
The ICard and Triage common-antigen tests had some of the highest sensitivities of all IAs, but both suffer from the fact that they are unable to distinguish toxigenic from nontoxigenic infections. Of these two tests, the Triage was found to be superior. Again, these differences were maintained in their predictive values. Some consideration may, however, be given to the use of these tests in their panel form (i.e., the detection of antigen and toxin A). The value of these panels appears to lie in the individual strengths of each component: while the antigen portions of these tests provide very good NPVs and are therefore useful in ruling out disease in the vast majority of cases, the toxin portions of these tests have reasonable PPVs compared to direct CBA and therefore would be expected to detect many cases of CDD. However, it must be remembered that the CBA, when performed directly on feces, is expected to only detect 60 to 85% of all cases. By extrapolation, any of these IAs will therefore have an ultimate sensitivity of between 34 and 76%, with the ICard and Triage toxin tests at the bottom of this range.
To attain maximal sensitivity, any of these tests, including direct CBA, must be supplemented by an additional method to confirm negative results. While nucleic acid amplification of C. difficile toxin genes in stool remains an option, toxigenic culture is by far the most commonly recommended confirmatory method, and the Society for Healthcare Epidemiology of America in fact recommends culture in addition to direct fecal toxin testing (5, 8, 13, 20, 26) . Toxigenic culture and one of the rapid methods evaluated in this study could be combined in a single algorithm as follows: (i) all fecal samples would be tested with an IA test; (ii) samples displaying a positive result would be signed out appropriately; (iii) negative samples would be sent on for confirmatory testing by toxigenic culture. If Triage were used as the initial test, the algorithm might be modified as follows to make use of the high NPV of the antigen portion of the panel: (i) all fecal samples would be tested with Triage; (ii) samples displaying concordant antigen and toxin results (i.e., negative/negative or positive/positive) would be so reported; (iii) samples giving discordant results would be sent on for confirmatory testing by toxigenic culture. A limitation of this algorithm is that it is not clear that the sensitivity of the Triage test is sufficiently high to report antigen-negative samples as being truly negative for C. difficile. Further analysis is required to resolve this issue.
HSCT patients frequently develop diarrhea due to both C. difficile and intestinal graft-versus-host disease during the first 100 days posttransplantation (7) . Treatments for CDD and graft-versus-host disease differ greatly, and incorrect treatment can lead to exacerbation of disease. Since 45% of our study samples were drawn from an HSCT population, we decided to stratify the performance of these IAs with respect to HSCT. No significant differences in sensitivity or specificity were detected.
Several limitations were inherent to this study. First, no independent method of discrepancy analysis was used. Four CBA-negative samples tested toxin positive by two or more IAs (data not shown), suggesting true positivity. Whether these were in fact CBA false negatives is unknown. Likewise, 12 samples were positive by CBA only (data not shown). Given the superior analytical sensitivity of CBA, the majority of these can be expected to be true positives. However, since our version of the CBA uses C. sordellii antitoxin instead of C. difficile antitoxin B, some of these "false negatives" may in fact be due to the presence of C. sordellii. C. sordellii produces two exotoxins, LT and HT, and is occasionally associated with nondiarrheal illnesses (1). Diarrheal disease due to toxigenic C. sordellii has not been reported, but this species can be part of the human colonic flora (1). While the incidence of C. sordellii in our population is unknown, it may have been responsible for some positive CBA/negative IA results. The second limitation lies in the choice of our reference method (i.e., direct fecal analysis for C. difficile toxin B by CBA). While this method is thought to be the best direct method of detection, it is not 100% sensitive, as noted above. Thus, any determination of sensitivity when using the direct CBA as a reference method VOL. 41, 2003 EVALUATION OF SIX C. DIFFICILE IMMUNOASSAYS 669 must take this into consideration. Studies relying on clinical case criteria may more appropriately address this question. Finally, a word must be said about the effects of disease prevalence on calculated predictive values. The PPV of a test is directly related to prevalence, while the NPV is inversely related to prevalence (6) . Therefore, whether a test is appropriately applied (i.e., only where a strong clinical index of suspicion exists) will have an effect on predictive values. This study was laboratory based in that it relied only on stool samples received for C. difficile toxin testing and made no effort to correlate test results with clinical impressions. We can therefore make no statements regarding pretest probability of disease, but we think that physician-ordering practices of other institutions are similar to ours.
In conclusion, while none of the rapid IAs evaluated here equaled the performance of direct fecal CBA, several did approach it and in fact gave useful predictive values. These tests, particularly the single use Triage and ICard tests, offer significant advantages over CBA and may therefore be considered for use in clinical microbiology laboratories, particularly those that do not have tissue culture facilities. Additionally, any of these tests have the potential to be used in conjunction with toxigenic culture to attain maximal sensitivity.
